Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.

Ye Guo(Shanghai East Hospital), Jin Li(Shanghai Cancer Institute), Zhixiang Zhuang(Soochow University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Weimin Ding(Zhujiang Hospital), Zuoxing Niu(Shandong Tumor Hospital), Aibing Xu(Nantong Tumor Hospital), Yufeng Cheng(Qilu Hospital of Shandong University), Yi Gao(Southwest Jiaotong University), Yuxian Bai(Harbin Medical University), Meili Sun(Jinan Central Hospital), Wei Li(First Hospital of Jilin University), Ping Chen(Macau University of Science and Technology), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Yangqing Huang(Shanghai Public Health Clinical Center), Lichun Deng(Jiangyin People's Hospital), Chunwang Yuan(Capital Medical University), Xiaoyu Yin(Verizon (United States)), Xu Zhu(Children's Hospital of Chongqing Medical University)
Journal of Clinical Oncology
January 24, 2023
10.1200/jco.2023.41.4_suppl.572
Cited by 11

Related Papers

Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
|The Lancet|2023|461